GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (FRA:AX9) » Definitions » Common Stock

Akebia Therapeutics (FRA:AX9) Common Stock : €0.0 Mil (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Common Stock?

Akebia Therapeutics's quarterly common stock stayed the same from Sep. 2023 (€0.0 Mil) to Dec. 2023 (€0.0 Mil) and stayed the same from Dec. 2023 (€0.0 Mil) to Mar. 2024 (€0.0 Mil).

Akebia Therapeutics's annual common stock increased from Dec. 2021 (€0.0 Mil) to Dec. 2022 (€0.0 Mil) but then stayed the same from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€0.0 Mil).


Akebia Therapeutics Common Stock Historical Data

The historical data trend for Akebia Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Common Stock Chart

Akebia Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Akebia Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Akebia Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Akebia Therapeutics (FRA:AX9) Business Description

Traded in Other Exchanges
Address
245 First Street, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (FRA:AX9) Headlines

No Headlines